On June 16, 2021 Helix BioPharma Corp. (TSX: "HBP"), a an immuno-oncology company developing drug
candidates for the prevention and treatment of cancer, reported its financial results for the fiscal third quarter
ended April 30, 2021(Press release, Helix BioPharma, JUN 14, 2021, View Source [SID1234584026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OVERVIEW

The Company reported a net loss and total comprehensive loss of $2,554,000 and $5,268,000 for the three and
nine-month periods ended April 30, 2021. For the three and nine-month periods ended April 30, 2020, net loss and
total comprehensive loss totalled $2,489,000 and $6,896,000, respectively. The net loss and total comprehensive
loss for the three-month period ending April 30, 2021, includes a net loss of $nil (2020 – $198,000) and for the ninemonth period ending April 30, 2021 a gain of $1,536,000 (2020 – loss of $465,000) from discontinued operations.

The Company lost control of its subsidiary in Poland during the three-month period ending October 31, 2020 though
continued to exert significant influence until December 22, 2020 when the Company disposed of its remaining interest for gross proceeds of $2,308,000.